Skip to content
Company Analysis

BioNTech SE BNTX

A comprehensive view of key metrics, scores, and financial health for BioNTech SE

Overview of BioNTech SE

BNTX NMS
Healthcare Biotechnology Framework: Biotech / Pre-Revenue Large Cap
BioNTech SE (BNTX), is a Large Cap company, in the Biotechnology industry, last closed at $87.06, about 80.3% overvalued vs fair value, -15.8% 1Y return, ranked 544/1145 in sector.
Metrics Rev Growth 4.3% ROE -5.9% Gross Margin 77.6%
USD 87.06
0.23%
(Delayed)
• Vol 90d: 48.2%
52-Week Range
Market Cap
$21.87B
Enterprise Value
$11.38B
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Growth
Weak
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Completeness: 88%
Confidence: 91%
Updated: Oct 24
Top Beats

Quick Facts

Website https://www.biontech.de
HQ Mainz
Employees 6,772
Fiscal year Dec 31

Next Events

Earnings Nov 3 Call: Nov 3

Fair Value Snapshot

Bear Base Bull
$15
$17
$20
Current: $87.06 -80% vs base

Engine Room Money Flow™

Large Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
EUR 7.7B
-21.4%%
Total Revenue
EUR 2.9B
4.3%%
Net Income
-EUR 1.1B
-70.8%%
Operating Expense
EUR 2.9B
-1.7%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

R&D Intensity
73.4%
Excellent

High R&D focus - strong innovation commitment

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
1
Active Leaks
0/1
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating BioNTech SE's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
58
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Cost Leadership Position Operating margin at 76.9th percentile with strong OpEx control demonstrates cost leadership.
  • Consistent Cash Generation Cash generation is strong and consistent (score 0.87).

Key risks

  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.09), suggesting weak customer stickiness.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
51
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Pre-Revenue Biotech vs Industry Peers 67% Coverage
Trade-Off Triangle Visualization A ternary plot showing BNTX's balance between Growth (36.2%), Profitability (19.9%), and Safety (43.9%). Growth 36% Safety 44% Profitability 20%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

60th percentile vs peers
61
Key Signals
TSR 8.0% 60p
Strengths
  • Cash to Debt Ratio in top 20% of peers (28.70, 82th percentile)
  • Growth above peer median with strong metric coverage (100%)
  • Strong liquidity position vs peers
Risks

No significant risks identified for this axis.

Profitability

- vs peers
-
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

73th percentile vs peers
73
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for BioNTech SE.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$17.17
- - -
-80.3% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000